BPC-157 vs TB-500

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a partial sequence found in gastric juice proteins. Preclinical research has demonstrated its effects on angiogenesis, growth factor upregulation, and tissue repair across multiple organ-system models. It is studied in both reconstituted and oral-administration formats, with the oral route particularly relevant to gastrointestinal research. TB-500 is a synthetic fragment of thymosin beta-4, a 43-amino-acid protein involved in cell migration and differentiation. Preclinical studies have examined its role in tissue repair, inflammation modulation, and actin upregulation. TB-500 is commonly used in research protocols involving connective tissue and wound-healing models.

BPC-157

Origin Gastric juice derived
Primary Research Area GI and connective-tissue models
Research Format Reconstituted solution or oral
Typical Protocol Daily administration
Synergy Stacks well with TB-500
Starting Price $19

TB-500

Origin Thymus derived
Primary Research Area Tissue repair and inflammation models
Research Format Reconstituted solution
Typical Protocol 2-3x per week
Synergy Stacks well with BPC-157
Starting Price $24

The Verdict

BPC-157 and TB-500 act through different but complementary pathways in preclinical tissue-repair research. BPC-157 is most studied for localized effects in GI and connective-tissue models and can be administered orally. TB-500 has broader systemic activity in inflammation and repair models. Many researchers study them together as a stack, as their mechanisms complement each other without overlap. Choosing one over the other depends on the specific area of research interest, though the combination is the most popular approach.

BPC-157 vs TB-500 — FAQ

Can BPC-157 and TB-500 be used together in research?
Yes, BPC-157 and TB-500 are frequently stacked in research protocols. They operate through different mechanisms and are considered complementary. Many researchers report enhanced outcomes in preclinical models when using both peptides simultaneously.
Is oral BPC-157 as effective as reconstituted in research?
Oral BPC-157 has shown activity in preclinical research, particularly for gastrointestinal models. For systemic or connective-tissue targets, the reconstituted form may provide more direct delivery. Both administration routes have supporting research data.
What is a typical TB-500 research protocol duration?
Most research protocols report observable changes within 2-4 weeks of consistent administration. A typical loading phase of 4-6 weeks at higher concentrations is followed by a maintenance phase. Response times vary based on the specific model being studied.
What is the regulatory status of BPC-157 and TB-500?
Neither BPC-157 nor TB-500 is approved for human use. They are sold as research-use-only peptides for in-vitro and preclinical research applications.

References

Primary sources for key clinical and regulatory claims on this page.

  1. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing — PubMed / Front Pharmacol . Frequently cited review source for BPC-157 wound-healing, angiogenesis, and tendon or gut-repair mechanisms.
  2. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues — PubMed / Trends Mol Med . Primary source commonly used to describe thymosin beta-4 repair biology that underpins TB-500 positioning.

Keep Researching

Use the surrounding category and guide pages to move from a side-by-side comparison into the broader decision path.

Research Peptides CategoryRecovery Hub
Updated March 2026. This comparison is reviewed for catalog accuracy, sourcing language, and consistency with our public quality standards. It is an educational summary for research reference only. Read our Editorial Standards.

Ready to order?

Pick your product and check out in under 3 minutes.

Shop Now